The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications

Annals of Translational Medicine

Volumn 4, Issue 9, 2016, Pages

  Economopoulou, Panagiota ^a   Perisanidis, Christos ^b   Giotakis, Evaggelos I ^c   Psyrri, Amanda ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

Checkpoint inhibitors; Head and neck cancer; Immune system; Immunotherapy

Indexed keywords

ADX 11 001; AVELUMAB; CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; DOCETAXEL; DURVALUMAB; ENOBLITUZUMAB; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR MONOCLONAL ANTIBODY; MELANOMA ANTIGEN; MELANOMA ANTIGEN E A3; METHOTREXATE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; NIVOLUMAB; PANITUMUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PROTEIN E6; PROTEIN E7; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; WART VIRUS VACCINE; ZALUTUMUMAB;

ADOPTIVE TRANSFER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; WART VIRUS;

EID: 85006207168     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2016.03.34     Document Type: Review

References (81)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009;101:412-23.
3. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-47.
4. Baxi S, Fury M, Ganly I, et al. Ten years of progress in head and neck cancers. J Natl Compr Canc Netw 2012;10:806-10.
5. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
6. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
7. Raval RR, Sharabi AB, Walker AJ, et al. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2014;2:14.
8. Mendes F, Domingues C, Rodrigues-Santos P, et al. The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. Biochim Biophys Acta 2016;1865:168-75.
9. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296:298-300.
10. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
12. Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 2015;36:250-6.
13. Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013;1:16.
14. Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol 2015;42:663-71.
15. Varilla V, Atienza J, Dasanu CA. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 2013;13:1241-56.
16. Schoenfeld JD. Immunity in head and neck cancer. Cancer Immunol Res 2015;3:12-7.
17. Chikamatsu K, Sakakura K, Whiteside TL, et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 2007;29:120-7.
18. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865-78.
19. Reichert TE, Strauss L, Wagner EM, et al. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
20. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553-62.
21. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumorinfiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-81.
22. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72.
23. Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012;75:95-101.
24. Badoual C, Hans S, Fridman WH, et al. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 2009;27:e5-6; author reply e7.
25. Sun W, Li WJ, Wu CY, et al. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res 2014;33:35.
26. Schaefer C, Kim GG, Albers A, et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-20.
27. van der Burg SH. Immunotherapy of human papilloma virus induced disease. Open Virol J 2012;6:257-63.
28. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
29. Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-38.
30. Vasilakopoulou M, Rampias T, Sasaki C, et al. Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma. J Clin Oncol 2013;31:abstr 6012.
31. Näsman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012;7:e38711.
32. Lukesova E, Boucek J, Rotnaglova E, et al. High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed Res Int 2014;2014:303929.
33. Qian X, Ma C, Nie X, et al. Biology and immunology of cancer stem(-like) cells in head and neck cancer. Crit Rev Oncol Hematol 2015;95:337-45.
34. Krishnamurthy S, Nor JE. Head and neck cancer stem cells. J Dent Res 2012;91:334-40.
35. Jewett A, Tseng HC, Arasteh A, et al. Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv 2012;9:5-16.
36. Tang AL, Owen JH, Hauff SJ, et al. Head and neck cancer stem cells: the effect of HPV-an in vitro and mouse study. Otolaryngol Head Neck Surg 2013;149:252-60.
37. Zhang M, Kumar B, Piao L, et al. Elevated intrinsic cancer stem cell population in human papillomavirusassociated head and neck squamous cell carcinoma. Cancer 2014;120:992-1001.
38. Qian X, Wagner S, Ma C, et al. ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. Oncol Rep 2013;29:1777-84.
39. Chen YW, Chen KH, Huang PI, et al. Cucurbitacin I suppressed stem-like property and enhanced radiationinduced apoptosis in head and neck squamous carcinoma-derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 2010;9:2879-92.
40. Bourguignon LY, Wong G, Earle C, et al. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012;287:32800-24.
41. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
42. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304.
43. Leibowitz MS, Andrade Filho PA, Ferrone S, et al. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 2011;60:525-35.
44. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
45. Lalami Y, Awada A. Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev 2016;43:113-23.
46. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013;49:1089-96.
47. Allen C, Duffy S, Teknos T, et al. Nuclear factorkappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007;13:3182-90.
48. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
49. Sato T, Terai M, Tamura Y, et al. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011;51:170-82.
50. Melero I, Rouzaut A, Motz GT, et al. T-cell and NKcell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014;4:522-6.
51. Nagaraj S, Schrum AG, Cho HI, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-16.
52. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
53. Balermpas P, Rodel F, Liberz R, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer 2014;111:1509-18.
54. Fujii N, Shomori K, Shiomi T, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 2012;41:444-51.
55. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72:3125-30.
56. Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 2006;42:268-74.
57. Cho YA, Yoon HJ, Lee JI, et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011;47:1148-53.
58. Skeate JG, Woodham AW, Einstein MH, et al. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother 2016. [Epub ahead of print].
59. Venuti A, Curzio G, Mariani L, et al. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models. Cancer Immunol Immunother 2015;64:1329-38.
60. Schiller JT, Castellsague X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26 Suppl 10:K53-61.
61. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
62. Gildener-Leapman N, Lee J, Ferris RL. Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol 2014;50:780-4.
63. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 2003;3:973-83.
64. Voskens CJ, Sewell D, Hertzano R, et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 2012;34:1734-46.
65. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008;26:5315-20.
66. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76.
67. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
68. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
69. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013;4:76.
70. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710.
71. Saloura V, Cohen EE, Licitra L, et al. An open-label singlearm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2014;73:1227-39.
72. Basavaraj C, Sierra P, Shivu J, et al. Nimotuzumab with chemoradiation confers a survival advantage in treatmentnaive head and neck tumors over expressing EGFR. Cancer Biol Ther 2010;10:673-81.
73. Seiwert TY, Gupta S, Mehra R, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol 2015;33:abstr LBA6008.
74. Fury M, Ou SH, Balmanoukian A, et al. Clinical activity and safety of MEDI4736, an Anti-PD-L1 Antibody, In Head and Neck Cancer. ESMO Meeting 2014. Poster # 988PD. Abstract ID 5656.
75. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132:315-25.
76. Inoue K, Saegusa N, Omiya M, et al. Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model. Cancer Sci 2015;106:143-50.
77. Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014;20:2433-44.
78. Whiteside TL, Ferris RL, Szczepanski M, et al. Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma. Head Neck 2016;38 Suppl 1:E494-501.
79. To WC, Wood BG, Krauss JC, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000;126:1225-31.
80. Jiang P, Zhang Y, Wang H, et al. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol 2015;28:208-14.
81. Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 2014;22:132-9.